Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Name: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
License: Public Domain

Roswell Park Cancer Institute

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

digestive system neuroendocrine neoplasm, lung neuroendocrine neoplasm, malignant solid neoplasm, pancreatic neuroendocrine neoplasm

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 195398
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.